{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:35:21Z","timestamp":1782531321145,"version":"3.54.5"},"reference-count":26,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>\n                    Daily short intravenous interleukin-2 (IL-2) infusions have been developed to decrease toxicity while maintaining the anticancer activity of this agent against melanoma. Such IL-2 schedules have previously been shown to promote lymphokine-activated killer cell (LAK) activity. Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes. Twenty-one patients with metastatic melanoma were treated with IL-2 18 million IU\/m\n                    <jats:sup>2<\/jats:sup>\n                    intravenously (i.v.) over 15\u201330 minutes and famotidine 20\u2009mg i.v. daily for 3 days for 6 consecutive weeks on an outpatient basis. Cycles were repeated every 8 weeks. Patient characteristics: 13 males\/8 females, median age, 51 (range: 26\u201379), and median Eastern Cooperative Oncology Group performance status, 1; common metastatic sites: lymph nodes (16), lungs (14), subcutaneous (8), liver (7), and bone (7). Prior systemic therapy: chemotherapy (7); IL-2 (7); and interferon (5). Most common toxicities were myalgia\/arthralgia, rigors, nausea\/emesis, and mild elevation of liver function tests. No patients required hospitalization for toxicity of therapy. One patient (5%) has had a complete response (ongoing at 29+ months), while 4 other patients (19%) had partial responses (total response rate: 24%; 95% confidence interval: 9%\u201348%). Responses occurred in lung, spleen, bones, lymph nodes, and subcutaneous sites. Median response duration=20+ months. Outpatient intravenous IL-2 and famotidine has activity in melanoma.\n                  <\/jats:p>","DOI":"10.1089\/cbr.2012.1239","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T01:41:01Z","timestamp":1340761261000},"page":"442-445","source":"Crossref","is-referenced-by-count":5,"title":["Outpatient Intravenous Interleukin-2 with Famotidine Has Activity in Metastatic Melanoma"],"prefix":"10.1177","volume":"27","author":[{"suffix":"Jr.","given":"Walter D.Y.","family":"Quan","sequence":"first","affiliation":[{"name":"Loma Linda University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Quan","sequence":"additional","affiliation":[{"name":"Loma Linda University Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Perez","sequence":"additional","affiliation":[{"name":"Loma Linda University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Johnson","sequence":"additional","affiliation":[{"name":"Loma Linda University Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.4.1335"},{"key":"e_1_3_2_4_2","first-page":"3680","article-title":"Lymphokine-activated killer activity induced by in vivo Interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens","volume":"49","author":"Weil-Hillman G","year":"1989","unstructured":"Weil-Hillman G, , Fisch P, , Prieve AF et al. Lymphokine-activated killer activity induced by in vivo Interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens. Cancer Res, 1989; 49:3680.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_2_5_2","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update","volume":"6","author":"Atkins MB","year":"2000","unstructured":"Atkins MB, , Kunkel L, , Sznol M et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am, 2000; 6,suppl1:S11.","journal-title":"Cancer J Sci Am"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.486"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.694"},{"key":"e_1_3_2_8_2","first-page":"128","article-title":"Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma","volume":"65","author":"Mitchell MS","year":"1989","unstructured":"Mitchell MS, , Kempf RA, , Harel W et al. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull NY Acad Med, 1989; 65:128.","journal-title":"Bull NY Acad Med"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200305000-00012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(92)90107-V"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602760169415"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/1084978041424972"},{"key":"e_1_3_2_14_2","first-page":"770","article-title":"Continuous infusion plus pulse interleukin-2 and famotidine in melanoma","volume":"19","author":"Quan W","year":"2004","unstructured":"Quan WJr., , Ramirez M, , Taylor WC et al. Continuous infusion plus pulse interleukin-2 and famotidine in melanoma. Cancer Biother Radiopharm, 2004; 19:770.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.477"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.622"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1233"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<1::AID-CNCR2820680102>3.0.CO;2-K"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.249"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.17.1250"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205237"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199205000-00007"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0737"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1138"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.641"},{"key":"e_1_3_2_27_2","first-page":"609","article-title":"Continuous infusion Interleukin-2 and intravenous famotidine in metastatic melanoma","volume":"21","author":"Quan WDY","year":"2006","unstructured":"Quan WDYJr., , Milligan KS, , Quan FM et al. Continuous infusion Interleukin-2 and intravenous famotidine in metastatic melanoma. Cancer Biother Radiopharm, 2006; 21:609.","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2012.1239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2012.1239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2012.1239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:13:38Z","timestamp":1777385618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/cbr.2012.1239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1089\/cbr.2012.1239"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2012.1239","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}